Cita APA

Fala, L. (2015). Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer. Am Health Drug Benefits.

Citación estilo Chicago

Fala, Loretta. "Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved By the FDA for the Treatment of Patients With Differentiated Thyroid Cancer." Am Health Drug Benefits 2015.

Cita MLA

Fala, Loretta. "Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved By the FDA for the Treatment of Patients With Differentiated Thyroid Cancer." Am Health Drug Benefits 2015.